The organic cation transporter, OCT1 [SLC22A1], expressed in abundance in the liver, mediates the uptake of small molecular weight hydrophilic organic cations including many drugs, nutrients and toxins. Although OCT1 clearly plays a role in the hepatic disposition of xenobiotics, its physiologic role is unknown. Recently, in preliminary studies, we made a striking and unexpected observation. We observed that knocking out Oct1 markedly reduced fatty liver in leptin deficient mice suggesting that OCT1 plays a critical role in triglyceride accumulation in the liver. The overall goals of the studies proposed in this renewal application are to determine the physiologic role of OCT1 and to explore the pharmacologic inhibition of OCT1 as a therapeutic strategy for fatty liver. Our underlying hypothesis is that OCT1 facilitates triglyceride accumulation in the liver.
Three aims are proposed. In studies under Aims 1 and 2, we will identify the pathways through which Oct1 acts on triglyceride accumulation using Oct1 knockout mice (Aim 1) and transgenic mice over- expressing human OCT1 in the liver (Aim 2). Two models of fatty liver will be used: leptin deficient mice, ob/ob, which represent a genetic deficiency model and mice fed high fat Western diets, which mimics the disease in U.S. populations.
In Aim 3, we will test small molecule inhibitors of human OCT1 as potential therapies for fatty liver. These studies will greatly advance our understanding of OCT1, a critical hepatic transporter involved in the disposition of xenobiotics.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Okita, Richard T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Pharmacy
San Francisco
United States
Zip Code
Chen, Ligong; Shu, Yan; Liang, Xiaomin et al. (2014) OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A 111:9983-8
Yee, Sook Wah; Chen, Ligong; Giacomini, Kathleen M (2012) The role of ATM in response to metformin treatment and activation of AMPK. Nat Genet 44:359-60
Minematsu, Tsuyoshi; Giacomini, Kathleen M (2011) Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 10:531-9
Li, Shuanglian; Chen, Ying; Zhang, Shuzhong et al. (2011) Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice. Pharm Res 28:610-25
Choi, J H; Yee, S W; Ramirez, A H et al. (2011) A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther 90:674-84
More, Swati S; Itsara, Melissa; Yang, Xiaodong et al. (2011) Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res 17:2339-49
Kido, Yasuto; Matsson, Pär; Giacomini, Kathleen M (2011) Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem 54:4548-58
More, Swati S; Akil, Omar; Ianculescu, Alexandra G et al. (2010) Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci 30:9500-9
Ianculescu, Alexandra G; Friesema, Edith C H; Visser, Theo J et al. (2010) Transport of thyroid hormones is selectively inhibited by 3-iodothyronamine. Mol Biosyst 6:1403-10
Chen, Ligong; Takizawa, Miho; Chen, Eugene et al. (2010) Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther 335:42-50

Showing the most recent 10 out of 70 publications